Cover Image
市場調查報告書

抗生素:契約條件·協定內容

Global Antibiotics Partnering Terms and Agreements 2010 to 2016

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品編碼 270198
出版日期 內容資訊 英文 219 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
抗生素:契約條件·協定內容 Global Antibiotics Partnering Terms and Agreements 2010 to 2016
出版日期: 2016年10月05日 內容資訊: 英文 219 Pages
簡介

本報告提供抗生素相關的各種合作契約趨勢調查分析,提供大製藥公司的各種合作概要,契約區分·產業部門·開發階段·各技術區分契約資料的目錄等彙整資料,為您概述為以下內容。

摘要整理

第1章 簡介

第2章 抗生素相關的各種聯盟趨勢

  • 簡介
  • 長年以來的抗生素聯盟
  • 大型製藥企業的抗生素交易活動
  • 大型生物工學企業的抗生素交易活動
  • 最活躍的抗生素交易
  • 抗生素聯盟:各類型交易
  • 抗生素聯盟:各疾病類型
  • 聯盟:各抗生素技術
  • 抗生素聯盟的平均交易條件
  • 抗生素聯盟結構
  • 抗生素交易結構

第3章 主要抗生素交易

  • 簡介
  • 主要交易:各金額

第4章 大型製藥公司的抗生素交易

  • 簡介
  • 大型製藥公司的抗生素聯盟交易利用法
  • 大型製藥公司的抗生素聯盟企業簡介

第5章 大生物工學公司抗生素交易

第6章 抗生素聯盟交易目錄

  • 簡介
  • 各企業(A-Z)
  • 各類型交易
    • 資產購買
    • 大型醫藥品企業的對外授權
    • 共同開發
    • 共同R&D
    • 共同行銷
    • 業務委託
    • 共同促銷
    • CRADA
    • 交叉授權
    • 開發
    • 流通銷售等
  • 各開發階段
    • 藥物研發
    • 上市
    • 處方製劑
    • 第一階段
    • 第二階段
    • 第三階段
    • 前臨床
    • 申請登記
  • 各治療領域
    • 心血管
    • 中樞神經系統
    • 牙科
    • 皮膚科
    • 消化器官科
    • 遺傳基因疾病
    • 泌尿生殖系統
    • 醫院照護
    • 免疫疾病
    • 感染疾病
    • 代謝
    • 肌肉骨骼
    • 癌症
    • 精神科
    • 公共衛生
    • 呼吸系統
    • 性的健康

第7章 抗生素交易:各技術類型

  • 簡介
  • 交易:各抗生素類型

附錄:聯盟資源中心

  • 網路夥伴合作
  • 合作夥伴活動
  • 參考資料

附錄

圖表

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: CP2119

The Global Antibiotics Partnering Terms and Agreements 2010 to 2016 report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Trends in antibiotics partnering deals
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Antibiotics partnering contract documents
  • Top antibiotics deals by value

The Global Antibiotics Partnering Terms and Agreements 2010 to 2016 report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter antibiotics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors antibiotics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest antibiotics agreements announced in the healthcare sectors, covering:

  • Antibiotics
  • Aminoglycosides
  • Cephalosporin
  • Clindamycin
  • Macrolides
  • Penicillin
  • Quinolones
  • Sulfonamides
  • Tetracycline

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains over 200 links to online copies of actual antibiotics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What are the precise rights granted or optioned?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of antibiotics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in antibiotics dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading antibiotics deals since 2010. Deals are listed by headline value, signed by big pharma, most active antibiotics dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in antibiotics dealmaking with a brief summary followed by a comprehensive listing of antibiotics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of antibiotics partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of antibiotics partnering deals signed and announced since Jan 2010. The chapter is organized by specific antibiotics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by antibiotics partnering company A-Z, deal type definitions and antibiotics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in antibiotics partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of antibiotics technologies and products.

Report scope

Global Antibiotics Partnering Terms and Agreements 2010 to 2016 is intended to provide the reader with an in-depth understanding and access to antibiotics trends and structure of deals entered into by leading companies worldwide.

Global Antibiotics Partnering Terms and Agreements 2010 to 2016 includes:

  • Trends in antibiotics dealmaking in the biopharma industry since 2010
  • Analysis of antibiotics deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life antibiotics deals
  • Access to over 200 antibiotics deal records and contract documents where available
  • The leading antibody deals by value since 2010
  • Most active antibiotics dealmakers since 2010
  • The leading antibiotics partnering resources

In Global Antibiotics Partnering Terms and Agreements 2010 to 2016, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy and technology target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Benefits

Global Antibiotics Partnering Terms and Agreements 2010 to 2016 provides the reader with the following key benefits:

  • In-depth understanding of antibiotics deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of antibiotics agreements with numerous real life case studies
  • Comprehensive access to over 200 antibiotics deals entered into by the world's biopharma companies, together with real world clause examples and contracts where available
  • Full listing of antibiotics deals by company A-Z, deal value, phase of development, deal type, and therapy focus
  • Identify leading antibiotics deals by value since 2010
  • Identify the most active antibiotics dealmakers since 2010
  • Detailed access to actual antibiotics contracts enter into by the leading fifty big pharma and big biotech companies
  • Insight into the terms included in a antibiotics agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in antibiotics dealmaking

  • 2.1. Introduction
  • 2.2. Antibiotics partnering over the years
  • 2.3. Most active antibiotics dealmakers
  • 2.4. Antibiotics partnering by deal type
  • 2.5. Antibiotics partnering by therapy area
  • 2.6. Antibiotics partnering by industry sector
  • 2.7. Deal terms for antibiotics partnering
    • 2.7.1 Antibiotics partnering headline values
    • 2.7.2 Antibiotics deal upfront payments
    • 2.7.3 Antibiotics deal milestone payments
    • 2.7.4 Antibiotics royalty rates
  • 2.8. The anatomy of an antibiotics deal
    • 2.8.a. Case study 1: RRD International & Dipexium Pharmaceuticals -Feb 03 2014
    • 2.8.b. Case study 2: Hospira & Cempra Pharmaceutical- July 01 2013
    • 2.8.c. Case study 3: Astellas & Optimer Pharmaceuticals- Feb 7 2011

Chapter 3 - Leading antibiotics deals

  • 3.1. Introduction
  • 3.2. Top antibiotics deals by value

Chapter 4 - Most active antibiotics dealmakers

  • 4.1. Introduction
  • 4.2. Most active antibiotics dealmakers
  • 4.3. Most active antibiotics partnering company profiles

Chapter 5 - Antibiotics contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Antibiotics contracts dealmaking directory

Chapter 6 - Antibiotics dealmaking by technology type

  • Antibiotics
  • Aminoglycosides
  • Cephalosporin
  • Clindamycin
  • Macrolides
  • Metronidazole
  • Penicillin
  • Quinolones
  • Tetracycline

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

  • Appendix 1 - Antibiotics deals by company A-Z
  • Appendix 2 - Antibiotics deals by stage of development
  • Appendix 3 - Antibiotics deals by deal type
  • Appendix 4 - Antibiotics deals by therapy area
  • Appendix 5 -Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Antibiotics partnering since 2010
  • Figure 2: Active antibiotics dealmaking activity- 2010 to 2016
  • Figure 3: Antibiotics partnering by deal type since 2010
  • Figure 4: Antibiotics partnering by disease type since 2010
  • Figure 5: Antibiotics partnering by industry sector since 2010
  • Figure 6: Antibiotics deals with a headline value
  • Figure 7: Antibiotics deals with an upfront value
  • Figure 8: Antibiotics deals with a milestone value
  • Figure 9: Antibiotics deals with a royalty rate value
  • Figure 10: Top antibiotics deals by value since 2010
  • Figure 11: Most active antibiotics dealmakers 2010 to 2016
  • Figure 12: Antibiotics partnering by technology type since 2010
  • Figure 13: Online partnering resources
  • Figure 14: Forthcoming partnering events
Back to Top